<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical significance of circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells (CTCs) including <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells (<z:chebi fb="11" ids="17437,53115">CSCs</z:chebi>) (CTC/<z:chebi fb="11" ids="17437,53115">CSC</z:chebi>) in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> drainage vein blood of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is unclear </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we investigated the prognostic value of CTC/<z:chebi fb="11" ids="17437,53115">CSC</z:chebi> that express carcinoembryonic antigen (CEA) cytokeratin 19 (CK19), CK20 and/or CD133 (CEA/CK/CD133) <z:chebi fb="2" ids="33699">mRNA</z:chebi> in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> drainage blood of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with Dukes' stage B and C </plain></SENT>
<SENT sid="2" pm="."><plain>We examined <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> drainage blood from 197 patients with Dukes' stage B and C <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>CTCs that expressed CEA, CK19, CK20 and CD133 <z:chebi fb="2" ids="33699">mRNA</z:chebi> were detected using the quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) assay </plain></SENT>
<SENT sid="4" pm="."><plain>Each <z:chebi fb="2" ids="33699">mRNA</z:chebi> level was normalized with GAPDH <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels </plain></SENT>
<SENT sid="5" pm="."><plain>In the relationship between the expression of CEA/CK/CD133 in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> drainage blood and clinicopathological factors, a significant correlation was observed between CEA/CK/CD133 expression and Dukes' stage (p&lt;0.041) </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with Dukes' stage B and C, disease-free (DFS) and overall survival (OS) of patients with CEA/CK/CD133 positive in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> drainage blood were significantly worse than that of marker gene negative patients </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, in patients with Dukes' stage A, no significant differences were shown between these groups </plain></SENT>
<SENT sid="8" pm="."><plain>By Cox progression analysis, it was shown that CEA/CK/CD133 <z:chebi fb="2" ids="33699">mRNA</z:chebi> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> drainage blood was an independent prognostic factor for DFS and OS in patients with Dukes' stage B and C </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that detecting CEA/CK/CD133 <z:chebi fb="2" ids="33699">mRNA</z:chebi> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> drainage blood by the real-time RT-PCR method would have a prognostic value in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with Dukes' stage B and C </plain></SENT>
</text></document>